Dear Editor,

We read with great interest the article by Esmail et al. and congratulate them on their results with topical insulin for recurrent corneal erosion (RCE). We agree RCE is a relatively common and painful condition that currently has limited treatment options.

We have studied the use of a fingerprick of autologous blood (FAB) as an alternative treatment for RCE. FAB treatment is readily available, and no specialist production or funding is required to start treatment. We have studied four patients, of whom three reported significant symptomatic relief with FAB alone, and there were no adverse effects reported (ESCRS poster 2021). Further research with larger sample sizes is needed to compare the relative efficacy of FAB and conventional treatment for patients with RCE syndrome.

The results of Esmail et al. [1] and our case reports provide options for efficient and affordable treatments for RCE, which may significantly improve the quality of life of affected patients. RCE syndrome is a chronic, relapsing condition with severe pain reported by many patients, and further work is needed to develop these novel treatments.